Nanomedicine targeting ferroptosis to overcome anticancer therapeutic resistance
- PMID: 37728804
- DOI: 10.1007/s11427-022-2340-4
Nanomedicine targeting ferroptosis to overcome anticancer therapeutic resistance
Abstract
A potential reason for the failure of tumor therapies is treatment resistance. Resistance to chemotherapy, radiotherapy, and immunotherapy continues to be a major obstacle in clinic, resulting in tumor recurrence and metastasis. The major mechanisms of therapy resistance are inhibitions of cell deaths, like apoptosis and necrosis, through drug inactivation and excretion, repair of DNA damage, tumor heterogeneity, or changes in tumor microenvironment, etc. Recent studies have shown that ferroptosis play a major role in therapies resistance by inducing phospholipid peroxidation and iron-dependent cell death. Some ferroptosis inducers in combination with clinical treatment techniques have been used to enhance the effect in tumor therapy. Notably, versatile ferroptosis nanoinducers exhibit an extensive range of functions in reversing therapy resistance, including directly triggering ferroptosis and feedback regulation. Herein, we provide a detailed description of the design, mechanism, and therapeutic application of ferroptosis-mediated synergistic tumor therapeutics. We also discuss the prospect and challenge of nanomedicine in tumor therapy resistance by regulating ferroptosis and combination therapy.
Keywords: cancer therapy; ferroptosis; nanoinducers; therapy resistance.
© 2023. Science China Press.
References
-
- Cao, K., Du, Y., Bao, X., Han, M., Su, R., Pang, J., Liu, S., Shi, Z., Yan, F., and Feng, S. (2022b). Glutathione-bioimprinted nanoparticles targeting of N6-methyladenosine FTO demethylase as a strategy against leukemic stem cells. Small 18, 2106558. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
